Trgovina Pieris Pharmaceuticals, Inc. - PIRS CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 0.05 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Pieris Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Predhodno. Zapri* | 0.73 |
Odpri* | 0.76 |
Enoletna sprememba* | -55.56% |
Dnevni razpon* | 0.73 - 0.81 |
Razpon 52 wk | 0.72-2.12 |
Povprečni obseg (10 dni) | 743.53K |
Povprečni obseg (3 meseci) | 13.81M |
Tržna kapitalizacija | 61.51M |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 82.02M |
Prihodki | 16.85M |
EPS | -0.56 |
Dividenda (donosnost v %) | N/A |
Beta | 1.08 |
Datum naslednjega zaslužka | Aug 2, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
May 30, 2023 | 0.73 | -0.05 | -6.41% | 0.78 | 0.78 | 0.72 |
May 26, 2023 | 0.72 | -0.08 | -10.00% | 0.80 | 0.85 | 0.72 |
May 25, 2023 | 0.79 | -0.04 | -4.82% | 0.83 | 0.84 | 0.79 |
May 24, 2023 | 0.85 | -0.02 | -2.30% | 0.87 | 0.88 | 0.84 |
May 23, 2023 | 0.89 | -0.03 | -3.26% | 0.92 | 0.92 | 0.86 |
May 22, 2023 | 0.84 | 0.02 | 2.44% | 0.82 | 0.84 | 0.77 |
May 19, 2023 | 0.79 | -0.07 | -8.14% | 0.86 | 0.87 | 0.78 |
May 18, 2023 | 0.83 | 0.02 | 2.47% | 0.81 | 0.94 | 0.79 |
May 17, 2023 | 0.76 | 0.00 | 0.00% | 0.76 | 0.79 | 0.74 |
May 16, 2023 | 0.77 | -0.05 | -6.10% | 0.82 | 0.82 | 0.77 |
May 15, 2023 | 0.83 | 0.00 | 0.00% | 0.83 | 0.85 | 0.78 |
May 12, 2023 | 0.84 | -0.08 | -8.70% | 0.92 | 0.92 | 0.82 |
May 11, 2023 | 0.93 | 0.12 | 14.81% | 0.81 | 0.96 | 0.76 |
May 10, 2023 | 0.84 | 0.06 | 7.69% | 0.78 | 0.84 | 0.75 |
May 9, 2023 | 0.82 | 0.02 | 2.50% | 0.80 | 0.82 | 0.73 |
May 8, 2023 | 0.80 | -0.02 | -2.44% | 0.82 | 0.84 | 0.79 |
May 5, 2023 | 0.83 | 0.05 | 6.41% | 0.78 | 0.85 | 0.78 |
May 4, 2023 | 0.77 | -0.03 | -3.75% | 0.80 | 0.84 | 0.74 |
May 3, 2023 | 0.79 | 0.03 | 3.95% | 0.76 | 0.80 | 0.72 |
May 2, 2023 | 0.74 | 0.03 | 4.23% | 0.71 | 0.74 | 0.70 |
Pieris Pharmaceuticals, Inc. Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
Wednesday, June 21, 2023 | ||
Čas (UTC) (UTC) 12:00 | Država US
| Dogodek Pieris Pharmaceuticals Inc Annual Shareholders Meeting Pieris Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Thursday, June 22, 2023 | ||
Čas (UTC) (UTC) 12:00 | Država US
| Dogodek Pieris Pharmaceuticals Inc Annual Shareholders Meeting Pieris Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 2, 2023 | ||
Čas (UTC) (UTC) 12:30 | Država US
| Dogodek Q2 2023 Pieris Pharmaceuticals Inc Earnings Release Q2 2023 Pieris Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Tuesday, October 31, 2023 | ||
Čas (UTC) (UTC) 12:30 | Država US
| Dogodek Q3 2023 Pieris Pharmaceuticals Inc Earnings Release Q3 2023 Pieris Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Skupni prihodki | 25.902 | 31.418 | 29.323 | 46.279 | 29.101 |
Prihodki | 25.902 | 31.418 | 29.323 | 46.279 | 29.101 |
Celotni odhodki iz poslovanja | 61.203 | 79.564 | 63.244 | 73.436 | 59.932 |
Celotna prodaja/splošni/upravni stroški Odhodki | 16.394 | 16.593 | 16.713 | 18.44 | 18.442 |
Raziskave in razvoj | 52.982 | 66.656 | 46.531 | 54.996 | 41.49 |
Prihodki iz poslovanja | -35.301 | -48.146 | -33.921 | -27.157 | -30.831 |
Prihodki (odhodki) od obresti, neto Neoperativni | 0.721 | 0.004 | 0.511 | 1.714 | 1.962 |
Drugo, neto | 1.303 | 2.404 | -3.656 | -0.026 | 1.803 |
Čisti dobiček pred obdavčitvijo | -33.277 | -45.738 | -37.066 | -25.469 | -27.066 |
Čisti dobiček po davkih | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
Čisti dobiček pred dodatnimi postavkami | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
Čisti dobiček | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
Total Adjustments to Net Income | -2.83 | ||||
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
Popravljen čisti dobiček | -33.277 | -45.738 | -37.23 | -28.299 | -26.754 |
Popravljene ponderirane povprečne delnice | 74.172 | 64.547 | 54.481 | 50.625 | 53.081 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.44865 | -0.7086 | -0.68336 | -0.55899 | -0.50402 |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.55884 | -0.76569 | -0.68336 | -0.55899 | -0.50402 |
Skupaj izredne postavke | |||||
Nenavadni odhodki (prihodki) | -8.173 | -3.685 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Skupni prihodki | 1.936 | 5.846 | 5.37 | 3.698 | 10.988 |
Prihodki | 1.936 | 5.846 | 5.37 | 3.698 | 10.988 |
Celotni odhodki iz poslovanja | 15.419 | 13.974 | 16.07 | 14.844 | 16.315 |
Celotna prodaja/splošni/upravni stroški Odhodki | 4.023 | 3.985 | 3.949 | 4.081 | 4.379 |
Raziskave in razvoj | 13.424 | 13.38 | 13.589 | 11.947 | 14.066 |
Prihodki iz poslovanja | -13.483 | -8.128 | -10.7 | -11.146 | -5.327 |
Prihodki (odhodki) od obresti, neto Neoperativni | 0.357 | 0.351 | 0.241 | 0.132 | -0.003 |
Drugo, neto | -0.057 | -0.325 | 0.723 | 0.676 | 0.229 |
Čisti dobiček pred obdavčitvijo | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Čisti dobiček po davkih | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Čisti dobiček pred dodatnimi postavkami | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Čisti dobiček | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Popravljen čisti dobiček | -13.183 | -8.102 | -9.736 | -10.338 | -5.101 |
Popravljene ponderirane povprečne delnice | 74.519 | 74.448 | 74.397 | 74.125 | 73.711 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.17691 | -0.10883 | -0.13087 | -0.13947 | -0.0692 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.20412 | -0.15438 | -0.1506 | -0.15544 | -0.0981 |
Nenavadni odhodki (prihodki) | -2.028 | -3.391 | -1.468 | -1.184 | -2.13 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 73.424 | 127.625 | 75.721 | 115.013 | 135.382 |
Denarna sredstva in kratkoročne naložbe | 59.169 | 117.764 | 70.436 | 104.154 | 128.107 |
Denarna sredstva in ustrezniki | 38.635 | 117.764 | 70.436 | 62.26 | 74.867 |
Celotne terjatve, neto | 5.81 | 3.313 | 1.706 | 6.787 | 2.701 |
Accounts Receivable - Trade, Net | 5.81 | 3.313 | 1.706 | 6.787 | 2.701 |
Prepaid Expenses | 8.445 | 6.548 | 3.579 | 4.072 | 4.574 |
Total Assets | 95.49 | 153.56 | 105.01 | 141.097 | 141.341 |
Property/Plant/Equipment, Total - Net | 20.697 | 23.031 | 25.98 | 22.938 | 5.049 |
Property/Plant/Equipment, Total - Gross | 30.344 | 30.748 | 31.795 | 26.505 | 8.415 |
Accumulated Depreciation, Total | -9.647 | -7.717 | -5.815 | -3.567 | -3.366 |
Other Long Term Assets, Total | 1.369 | 2.904 | 3.309 | 3.146 | 0.91 |
Total Current Liabilities | 36.583 | 50.561 | 22.145 | 27.003 | 48.076 |
Accounts Payable | 4.154 | 8.609 | 1.787 | 5.803 | 3.35 |
Accrued Expenses | 11.122 | 14.833 | 7.496 | 9.486 | 8.169 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 21.307 | 27.119 | 12.862 | 11.714 | 36.557 |
Total Liabilities | 67.561 | 102.805 | 73.983 | 89.745 | 101.406 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 30.978 | 52.244 | 51.838 | 62.742 | 53.33 |
Total Equity | 27.929 | 50.755 | 31.027 | 51.352 | 39.935 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.074 | 0.072 | 0.056 | 0.055 | 0.054 |
Additional Paid-In Capital | 318.53 | 306.998 | 242.672 | 227.468 | 189.929 |
Retained Earnings (Accumulated Deficit) | -290.421 | -257.144 | -211.406 | -174.176 | -147.066 |
Other Equity, Total | -0.254 | 0.829 | -0.295 | -1.995 | -2.982 |
Total Liabilities & Shareholders’ Equity | 95.49 | 153.56 | 105.01 | 141.097 | 141.341 |
Total Common Shares Outstanding | 74.5191 | 72.2227 | 56.0028 | 55.2124 | 54.1512 |
Kratkoročne naložbe | 20.534 | 0 | 41.894 | 53.24 | |
Long Term Investments | 0 | ||||
Total Preferred Shares Outstanding | 0.00762 | 0.00762 | 0.01443 | 0.01143 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 60.505 | 73.424 | 78.56 | 90.904 | 111.749 |
Denarna sredstva in kratkoročne naložbe | 48.379 | 59.169 | 69.823 | 80.936 | 100.268 |
Denarna sredstva in ustrezniki | 39.742 | 38.635 | 48.423 | 54.257 | 83.737 |
Celotne terjatve, neto | 1.055 | 5.81 | 0.829 | 1.264 | 1.644 |
Accounts Receivable - Trade, Net | 1.055 | 5.81 | 0.829 | 1.264 | 1.644 |
Prepaid Expenses | 11.071 | 8.445 | 7.908 | 8.704 | 9.837 |
Total Assets | 82.258 | 95.49 | 99.163 | 114.309 | 137.115 |
Property/Plant/Equipment, Total - Net | 20.502 | 20.697 | 19.296 | 21.047 | 22.693 |
Property/Plant/Equipment, Total - Gross | 30.476 | 30.344 | 27.615 | 29.292 | 30.87 |
Accumulated Depreciation, Total | -9.974 | -9.647 | -8.319 | -8.245 | -8.177 |
Other Long Term Assets, Total | 1.251 | 1.369 | 1.307 | 2.358 | 2.673 |
Total Current Liabilities | 42.875 | 36.583 | 33.521 | 35.546 | 39.484 |
Accounts Payable | 5.833 | 4.154 | 3.641 | 1.898 | 4.496 |
Accrued Expenses | 9.764 | 11.122 | 10.801 | 10.175 | 11.858 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 27.278 | 21.307 | 19.079 | 23.473 | 23.13 |
Total Liabilities | 66.8 | 67.561 | 63.396 | 69.944 | 83.665 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 23.925 | 30.978 | 29.875 | 34.398 | 44.181 |
Total Equity | 15.458 | 27.929 | 35.767 | 44.365 | 53.45 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.074 | 0.074 | 0.074 | 0.074 | 0.074 |
Additional Paid-In Capital | 319.414 | 318.53 | 317.488 | 316.249 | 314.668 |
Retained Earnings (Accumulated Deficit) | -303.604 | -290.421 | -282.319 | -272.583 | -262.245 |
Other Equity, Total | -0.426 | -0.254 | 0.524 | 0.625 | 0.953 |
Total Liabilities & Shareholders’ Equity | 82.258 | 95.49 | 99.163 | 114.309 | 137.115 |
Total Common Shares Outstanding | 74.5191 | 74.5191 | 74.4062 | 74.2576 | 74.0979 |
Total Preferred Shares Outstanding | 0.00762 | 0.00762 | 0.00762 | 0.00762 | 0.00762 |
Kratkoročne naložbe | 8.637 | 20.534 | 21.4 | 26.679 | 16.531 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Čisti prihodki/začetna postavka | -33.277 | -45.738 | -37.23 | -25.469 | -26.754 |
Denarna sredstva iz poslovanja | -59.932 | -7.66 | -45.896 | -52.467 | -1.066 |
Denarna sredstva iz poslovanja | 2.77 | 2.459 | 2.311 | 0.632 | 0.57 |
Nedenarne postavke | 3.945 | 5.094 | 5.236 | 4.491 | 3.389 |
Cash Taxes Paid | 0 | 0.908 | |||
Denarna sredstva Plačane obresti | |||||
Spremembe v obratnem kapitalu | -33.37 | 30.525 | -16.377 | -32.121 | 21.893 |
Denarna sredstva pri naložbenju | -21.236 | -0.949 | 39.212 | 9.838 | -8.875 |
Kapitalski izdatki | -1.041 | -0.949 | -2.726 | -2.462 | -1.698 |
Celotne druge postavke denarnih tokov pri naložbenju | -20.195 | 0 | 41.938 | 12.3 | -7.177 |
Denarna sredstva pri financiranju | 7.214 | 59.127 | 10.115 | 32.166 | 48.511 |
Izdaja (odplačilo) delnic, neto | 7.017 | 58.962 | 9.915 | 31.797 | 48.511 |
Učinki deviznih tečajev | -5.175 | -3.19 | 4.745 | -2.144 | -1.581 |
Neto sprememba denarnih sredstev | -79.129 | 47.328 | 8.176 | -12.607 | 36.989 |
Deferred Taxes | 0 | 0.164 | 0 | -0.164 | |
Postavke denarnega toka pri financiranju | 0.197 | 0.165 | 0.2 | 0.369 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.183 | -33.277 | -25.175 | -15.439 | -5.101 |
Cash From Operating Activities | -10.996 | -59.932 | -46.999 | -38.221 | -22.643 |
Cash From Operating Activities | 0.605 | 2.77 | 2.195 | 1.428 | 0.845 |
Non-Cash Items | 0.975 | 3.945 | 3.37 | 2.728 | 1.264 |
Changes in Working Capital | 0.607 | -33.37 | -27.389 | -26.938 | -19.651 |
Cash From Investing Activities | 11.903 | -21.236 | -22.343 | -27.813 | -16.948 |
Capital Expenditures | -0.048 | -1.041 | -1.052 | -1.018 | -0.389 |
Other Investing Cash Flow Items, Total | 11.951 | -20.195 | -21.291 | -26.795 | -16.559 |
Cash From Financing Activities | 0 | 7.214 | 7.121 | 6.839 | 6.558 |
Issuance (Retirement) of Stock, Net | 0 | 7.017 | 7.017 | 6.735 | 6.558 |
Foreign Exchange Effects | 0.2 | -5.175 | -7.12 | -4.312 | -0.994 |
Net Change in Cash | 1.107 | -79.129 | -69.341 | -63.507 | -34.027 |
Financing Cash Flow Items | 0.197 | 0.104 | 0.104 | ||
Deferred Taxes |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
BVF Partners L.P. | Hedge Fund | 25.1281 | 20609863 | 15529543 | 2023-05-11 | LOW |
Lynx1 Capital Advisors LLC | Investment Advisor | 8.6172 | 7067718 | 1439133 | 2023-03-31 | |
Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 5.551 | 4552876 | 0 | 2023-03-31 | |
Soleus Capital Management, L.P. | Hedge Fund | 5.0413 | 4134868 | 134868 | 2023-03-31 | HIGH |
Seagen Inc | Corporation | 4.5187 | 3706174 | 0 | 2022-12-31 | |
AstraZeneca PLC | Corporation | 4.37 | 3584230 | 0 | 2022-12-31 | LOW |
Pontifax Ltd. | Venture Capital | 4.3544 | 3571428 | 0 | 2021-12-31 | LOW |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.7632 | 2266350 | -125686 | 2023-03-31 | HIGH |
Citadel Advisors LLC | Hedge Fund | 2.4383 | 1999907 | -46254 | 2023-03-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 1.9744 | 1619387 | 52729 | 2023-01-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4366 | 1178283 | -114163 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.2626 | 1035540 | -29441 | 2023-03-31 | LOW |
Platinum Asset Management | Investment Advisor/Hedge Fund | 1.1888 | 975012 | -245786 | 2023-03-31 | LOW |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.769 | 630690 | -251144 | 2023-03-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7681 | 629965 | 0 | 2023-03-31 | LOW |
BMO Capital Markets (US) | Research Firm | 0.5873 | 481727 | 481727 | 2022-12-31 | MED |
Walleye Capital LLC | Hedge Fund | 0.5839 | 478935 | 478935 | 2023-03-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.4699 | 385391 | -301600 | 2023-03-31 | HIGH |
Cutter & Company, Inc. | Investment Advisor | 0.4602 | 377479 | -1000 | 2023-03-31 | LOW |
Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 0.429 | 351834 | -590000 | 2023-03-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group530K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$46M+
Mesečni obseg naložb
$31M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Pieris Pharmaceuticals, Inc. Company profile
O družbi Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. je biotehnološko podjetje v klinični fazi, ki odkriva in razvija zdravila na osnovi antikalina za zdravljenje potrjenih bolezenskih poti. Vodilni kandidat za zdravilo za dihala, ki temelji na anticalinu, je PRS-060/AZD1402, ki antagonizira IL-4R alfa, s čimer zavira IL-4 in IL-13, dva citokina, majhne beljakovine, ki posredujejo signale med celicami v človeškem telesu in so znani kot posredniki v vnetni kaskadi, ki povzročajo patogenezo astme in drugih vnetnih bolezni. Vodilni kandidat za zdravilo na osnovi IO Anticalin, ki je v pripravi, je cinrebafusp alfa, ki je zasnovan tako, da cilja na imunski receptor 4-1BB in tumorsko tarčo HER2. Cinrebafusp alfa je genetska fuzija različice protitelesa, usmerjenega proti HER2, z beljakovino Anticalin, specifično za 4-1BB.
Industry: | Bio Therapeutic Drugs |
225 Franklin Street
26Th Floor
BOSTON
MASSACHUSETTS 02110
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 530.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com